Global Human Insulin Market 2015-2019
Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy.
Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.
Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.Key vendors
Technavio Announces the Publication of its Research Report – Global Human Insulin Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Human Insulin Market: Lilly, Novo Nordisk and Sanofi
The other prominent vendors are: Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt and XOMA
Commenting on the report, an analyst from Technavio’s team said: “The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market.”
According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth.
Further, the report states that the global human insulin market is witnessing patent expiries for major brands.
Lilly, Novo Nordisk, Sanofi, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt, XOMA